ChinaDaily Briefs

Daily Brief China: Zephyrm Bioscience and more

In today’s briefing:

  • Pre-IPO Zephyrm Bioscience – Despite Promising Pipeline, Investment Risk Is High


Pre-IPO Zephyrm Bioscience – Despite Promising Pipeline, Investment Risk Is High

By Xinyao (Criss) Wang

  • There’s great potential for PSCs, which provides new treatment options for complex diseases where traditional therapies are ineffective.The more solid the platform technology, the greater the dividends in later stage.
  • Zephyrm’s pipeline candidates are promising. However, considering the R&D risks, the uncertainty of future commercialization and product safety profile, we think the investment risk of this Company is relatively high.
  • Valuation of overseas peers is not high. In our view, valuation performance of Zephyrm would be largely depend on its clinical results of pipeline, which is a gamble for investors.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars